Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review.

Biotechnology and Bioengineering
Melissa HolsteinZheng Jian Li

Abstract

To achieve the high protein concentrations required for subcutaneous administration of biologic therapeutics, numerous manufacturing process challenges are often encountered. From an operational perspective, high protein concentrations result in highly viscous solutions, which can cause pressure increases during ultrafiltration. This can also lead to low flux during ultrafiltration and sterile filtration, resulting in long processing times. In addition, there is a greater risk of product loss from the hold-up volumes during filtration operations. From a formulation perspective, higher protein concentrations present the risk of higher aggregation rates as the closer proximity of the constituent species results in stronger attractive intermolecular interactions and higher frequency of self-association events. There are also challenges in achieving pH and excipient concentration targets in the ultrafiltration/diafiltration (UF/DF) step due to volume exclusion and Donnan equilibrium effects, which are exacerbated at higher protein concentrations. This paper highlights strategies to address these challenges, including the use of viscosity-lowering excipients, appropriate selection of UF/DF cassettes with modified membranes and/or im...Continue Reading

References

Jun 20, 1977·Biochemical and Biophysical Research Communications·P D Ross, A P Minton
Jan 1, 1990·Critical Reviews in Biochemistry and Molecular Biology·P L Privalov
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·N Muramatsu, A P Minton
Jan 1, 1985·Methods in Enzymology·T Arakawa, S N Timasheff
Feb 1, 1996·Biophysical Journal·G B Strambini, E Gabellieri
Dec 1, 1996·Journal of Pharmaceutical Sciences·B S ChangJ F Carpenter
Dec 31, 1997·Journal of Pharmaceutical Sciences·X M LamJ L Cleland
Oct 3, 1999·Methods in Enzymology·J F CarpenterT W Randolph
Dec 1, 2000·Journal of Colloid and Interface Science·C C Ho, A L Zydney
May 4, 2002·Pharmaceutical Biotechnology·Theodore W Randolph, LaToya S Jones
May 30, 2002·Pharmaceutical Research·Michael J TreuheitDavid N Brems
Apr 4, 2003·Biotechnology and Bioengineering·Enhong CaoPeter R Foster
May 5, 2004·Journal of Pharmaceutical Sciences·Steven J ShireJun Liu
Aug 6, 2004·Journal of Pharmaceutical Sciences·Michael R StonerBrent S Kendrick
Jul 1, 1994·Acta Crystallographica. Section D, Biological Crystallography·A George, W W Wilson
Mar 12, 2005·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Hanns-Christian MahlerSusanne Matheus
Sep 17, 2005·Biotechnology and Bioengineering·Michael E LaskaNarahari S Pujar
Aug 1, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·L H BookbinderG I Frost
Dec 26, 2006·Biophysical Journal·Giovanni B Strambini, Margherita Gonnelli
Feb 2, 2008·Journal of Pharmaceutical Sciences·Sylvia KieseHanns-Christian Mahler
Sep 1, 1982·Biotechnology and Bioengineering·T J Narendranathan, P Dunnill
Jul 19, 2008·Biotechnology and Bioengineering·R van ReisH Lutz
Aug 8, 2008·Journal of Pharmaceutical Sciences·William F WeissChristopher J Roberts
Apr 17, 2009·Biotechnology and Bioengineering·Jared S BeeTheodore W Randolph
May 29, 2009·Journal of Pharmaceutical Sciences·Branden A SalinasTheodore W Randolph
Aug 26, 2009·Journal of Pharmaceutical Sciences·Sandeep YadavDevendra S Kalonia
Nov 3, 2009·Current Opinion in Biotechnology·Steven J Shire
Jan 22, 2010·Journal of Pharmaceutical Sciences·Hanns-Christian MahlerRobert Müller
Mar 2, 2010·International Journal of Pharmaceutics·Wei WangDirk Teagarden
Jun 15, 2010·Protein Engineering, Design & Selection : PEDS·Sheng-Jiun WuYiqing Feng
Aug 31, 2010·Journal of Pharmaceutical Sciences·Ravuri S K KishoreHanns-Christian Mahler
Sep 25, 2010·Journal of Pharmaceutical Sciences·Ge JiangManpreet-Vick S Wadhwa
Jul 26, 2011·Journal of Pharmaceutical Sciences·Steven D StroopScott D Leigh

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.